Navigation Links
New heart cells increase by 30 percent after stem cell infusion
Date:11/15/2011

ORLANDO, Fla. -- Healthy, new heart cells have been generated by animals with chronic ischemic heart disease after receiving stem cells derived from cardiac biopsies or "cardiospheres," according to research conducted at the University at Buffalo School of Medicine and Biomedical Sciences.

The research is being presented today (Nov. 15) at the Scientific Sessions of the American Heart Association in Orlando.

The UB research demonstrated a 30 percent increase in healthy heart muscle cells within a month after receiving cardiosphere-derived cells (or CDCs). This finding is contrary to conventional wisdom which has held that heart cells are terminally differentiated and thus, are unable to divide.

Ischemic heart disease from coronary artery narrowing and prior heart attacks is the most common cause of heart failure, the UB researchers explain. While other investigators have largely focused on regenerating muscle in scarred tissue, the UB group has shown that cardiac repair could be brought about by infusing the CDCs slowly into coronary arteries of the diseased as well as normal areas of the heart.

"Whereas most research has focused upon irreversible damage and scarring following a heart attack, we have shown that a single CDC infusion is capable of improving heart function in areas of the heart that are viable but not functioning normally," explains study co-author John M. Canty Jr., MD, the Albert and Elizabeth Rekate Professor of Medicine in the UB medical school and UB's chief of cardiovascular medicine.

He explains that areas of myocardial dysfunction without fibrotic scarring are common in patients with heart failure from coronary artery disease and that they arise from remodeling in response to a heart attack, as well as adaptations that develop from periods of inadequate blood flow, sometimes called hibernating myocardium.

"The rationale for our approach is somewhat analogous to planting seeds in fe
'/>"/>

Contact: Ellen Goldbaum
goldbaum@buffalo.edu
716-645-4605
University at Buffalo
Source:Eurekalert

Page: 1 2

Related medicine news :

1. No Benefit From Niacin for Heart Patients in Study
2. Stem Cells Show Promise in Healing Damaged Hearts
3. Fetal stem cells from placenta may help maternal heart recover from injury
4. Shock Fear May Curb Sex for People With Heart Devices
5. Low-Income Seniors at Greater Risk for Heart Failure
6. Mayo Clinic study confirms smoke-free workplaces reduce heart attacks
7. Novel, noninvasive measurement a strong predictor for heart failure in general population
8. Experimental Drug for Irregular Heart Rhythm Raises Death Risk: Study
9. Sugar-Sweetened Drinks May Pose Heart Risks to Women, Study Suggests
10. More Heart Attack Patients Take Meds When They Are Free
11. Stem cell study helps clarify the best time for therapy to aid heart attack survivors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Arbor, MI (PRWEB) October 22, 2014 ... of Schools of Allied Health Professions (ASAHP) Conference on ... Founder and CEO will participate in a panel discussion ... and Practice. , Isabel Healthcare provides a diagnostic decision ... in improving the diagnosis skills of students and clinical ...
(Date:10/22/2014)... Va. (PRWEB) October 22, 2014 ... Innovation , which is dedicated to distribute health ... of healthcare delivery worldwide announced the development of ... which patients expect when receiving healthcare. These are ... for patient-centered care: “providing care that is respectful ...
(Date:10/22/2014)... 22, 2014 Healthcare professionals who ... continuing education at home or on-the-go via laptops, ... 20 brand new, premium Seminar-on-Demand CE courses. The ... over 2,000 hours of CE course ... educational experience. With such a diverse library, there’s ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 ... fertilization (IVF) -- the incubation of embryos in a laboratory ... the vagina, new research suggests. Scientists from the United ... might sharply cut costs for pricey IVF procedures among certain ... those who don,t live near big-city assisted reproduction centers, the ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... Beth Israel Deaconess Medical Center (BIDMC) have received funding ... their 2009 Creativity Awards program, which supports innovative ideas ... , The one-year awards were made to 10 ... the only institution in New England to be funded ...
... 14 All it takes is "a big chunk of change" ... employee spearheaded the effort to raise more than $1,000 ... that supports families of children with congenital heart defects or heart ... checking account, we can start to do things that we,ve wanted ...
... April 14 Intrinsic Therapeutics, Inc. announced today that ... anular prosthesis for use in reconstructing soft tissues of ... to distribute the Barricaid throughout the European Union and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090414/NE98588LOGO ...
... Major Parkinson,s Organization to Launch Web Site Exclusively ... N.Y., April 14 The American Parkinson Disease ... a re-designed Web site, www.youngparkinsons.org , created ... (PD), their family members, friends, and healthcare providers. ...
... patients got temporary reprieve from daily injections , , ... of stem cell transplantation using the patient,s own cells ... of 23 patients newly diagnosed with type 1 diabetes ... patient even managed to go four years without needing ...
... STEWARTVILLE, Minn., April 14 Rochester Medical Corporation (Nasdaq: ... close on Thursday, April 30, 2009. The Company will ... report. The call will begin at 4:00 p.m. central ... Thomson/CCBN and can be accessed at Rochester Medical,s website at ...
Cached Medicine News:Health News:BIDMC scientists receive creativity awards from Prostate Cancer Foundation 2Health News:TAN's Efforts Produce 'Chunk of Change' for Children With Heart Defects 2Health News:Intrinsic Therapeutics Announces CE Mark for Barricaid Anular Prosthesis 2Health News:New Young Onset Parkinson's Disease Web Site Goes Live 2Health News:New Young Onset Parkinson's Disease Web Site Goes Live 3Health News:Stem Cells Buy Freedom From Insulin for Type 1 Diabetics 2Health News:Stem Cells Buy Freedom From Insulin for Type 1 Diabetics 3Health News:Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009 2
(Date:10/22/2014)... VERNE, Calif. , Oct. 22, 2014 /PRNewswire/ ... readiness products, has developed APLS ® Body ... that minimizes the spread of bacteria and virus ... APLS Body Guard Bio features a rugged, ... finished edges that create a leak-proof inner chamber ...
(Date:10/22/2014)... , October 22, 2014 ... ), a clinical-stage pharmaceutical company focused on ... reported positive top-line clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes. The ... States under a U.S. Food and ...
(Date:10/22/2014)... Colo. , Oct. 22, 2014   Surefire ... of infusion systems designed to maximize targeted delivery of ... pleased to announce that oncologist John R. Daniels ... Comprehensive Cancer Center, and surgical oncologist Steven C. ... have joined the Company,s Scientific Advisory Board (SAB).    ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... Dec. 12, 2011 /PRNewswire-iReach/ -- Reagent ... a common compliance concern driving Quality Control departments ... VerGo Pharma Research proves to be an innovative ... their business practices this month.  Harness ...
... Phase III clinical trial data presented today contribute ... Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in ... have deeper levels of response compared to those ... The findings from the ENEST (Evaluating Nilotinib Efficacy ...
Cached Medicine Technology:VerGo Integrates New Solution for Tracking Compliance Dates 2Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 2Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 3Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 4Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 5Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 6Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 7Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 8Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 9Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 10Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 11Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 12Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 13Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 14Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 15Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec® 16
Advanced Lighting System with Multi-Lamp Design providing Surgeon Focus Control and Extended, Variable Depth of Field over greater working distances. High Intensity, Cool Beam Temperature...
... technology that precisely focuses a column ... surgical site. Patented prism based technology ... illumination, shadow control, heat management and ... PrismAlix Series is available in a ...
... SureFlex™ line of reusable and autoclavable Lithotripsy ... This revolutionary and patented termination method accepts ... In the unlikely event you do manage ... face absolutely prevents damage to your laser ...
Up-tapered output compresses NA to give low NA fiber performance on high NA fiber stock....
Medicine Products: